Drug intelligence / Profile preview

PRX201

Development stage: Unknown
Lead developer: Prazer Therapeutics
Modality: Small Molecules

Overview

PRX201 is a small molecule drug candidate developed by Praser Therapeutics. It acts as an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), a signaling molecule implicated in inflammatory and neurodegenerative processes. The primary therapeutic area under investigation for PRX201 is nervous system diseases, with Alzheimer’s disease as its main active indication. As of the latest update, the drug remains in the discovery phase and has not advanced to clinical trials or regulatory approval[1][2].

Targets

RK (Ribokinase)

Beyond the preview

Go deeper on PRX201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRX201.

Explore the full profile